The 15 most recent market catalysts affecting $ZTS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
BNP Paribas Maintains Outperform on Zoetis, Lowers Price Target to $110
BNP Paribas analyst Navann Ty maintained an 'Outperform' rating on Zoetis (ZTS) but lowered the price target from $146 to $110. This action signals a more cautious outlook on the s…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Neutral on Zoetis, Lowers Price Target to $80
UBS analyst Andrea Alfonso maintained a 'Neutral' rating on Zoetis (ZTS) but lowered the price target from $85 to $80. This action indicates a slightly less optimistic valuation ou…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on Zoetis, Lowers Price Target to $115
JP Morgan analyst Chris Schott maintained an 'Overweight' rating on Zoetis, signaling continued confidence in the company's long-term prospects. However, the price target was lower…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds
Zoetis' Q2 results revealed a challenging environment for its companion animal segment, characterized by lower clinic visits, pet owner price sensitivity, and heightened competitio…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Zoetis shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.
This headline represents a significant corporate catalyst for Zoetis. Better-than-expected earnings typically lead to increased investor confidence and upward stock price movement,…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 65
Zoetis Announces Appointment Of Jay Saccaro As CFO And COO Effective August 17
The appointment of a new CFO and COO at Zoetis is a moderate corporate catalyst. While not directly impacting current earnings or revenue, a change in key leadership, especially in…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Zoetis Lowers FY2026 GAAP EPS Guidance from $6.35-$6.50 to $5.55-$5.65 vs $6.43 Est
Zoetis (ZTS) has issued a significant downward revision to its fiscal year 2026 GAAP EPS guidance, moving from a range of $6.35-$6.50 to $5.55-$5.65. This new forecast is notably b…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Zoetis Lowers FY2026 Adj EPS Guidance from $6.85-$7.00 to $6.15-$6.25 vs $6.88 Est; Lowers FY2026 Sales Guidance from $9.680B-$9.960B to $9.120B-$9.320B vs $9.726B Est
Zoetis announced a substantial reduction in its fiscal year 2026 adjusted EPS guidance from $6.85-$7.00 to $6.15-$6.25, and sales guidance from $9.680B-$9.960B to $9.120B-$9.320B. …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Zoetis Q2 Adj. EPS $1.87 Beats $1.86 Estimate, Sales $2.468B Miss $2.502B Estimate
Zoetis's Q2 earnings report presents a mixed picture for investors. While the adjusted EPS beat analyst consensus and showed strong growth year-over-year, the sales figures missed …
Jul 27, 2026
Market Technicals
Bearish
Impact 55
UBS Maintains Neutral on Zoetis, Lowers Price Target to $85
UBS analyst Andrea Alfonso lowered the price target for Zoetis (ZTS) from $99 to $85 while maintaining a Neutral rating. This action signals a more conservative outlook on the comp…
Jul 22, 2026
Corporate Catalyst
Bearish
Impact 55
Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $99
Morgan Stanley analyst Erin Wright has adjusted the price target for Zoetis (ZTS) from $115 to $99. This revision, while still accompanied by an 'Overweight' rating, signals a more…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 65
Zoetis Commercially Rolls Out Portela In Canada, EU To Treat Pain Associated With Osteoarthritis
Zoetis announced the commercial launch of Portela (relfovetmab) in Canada and the European Union. This is significant because Portela is the first long-acting anti-nerve growth fac…
Jul 17, 2026
Corporate Catalyst
Bearish
Impact 75
Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia
The ACCC has initiated a Phase 2 review of Zoetis' acquisition of Neogen's animal genomics business, citing concerns about diminished market competition and potential data monopoli…
Jul 17, 2026
Corporate Catalyst
Bearish
Impact 75
ACCC Subjects Zoetis' Acquisition Of Neogen Genomics Business To Phase 2 Review Over Competition Concerns
The ACCC's Phase 2 review indicates serious competition concerns, elevating the risk of the acquisition being delayed, modified, or even blocked. For Zoetis (ZTS), this could mean …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.